Biochemical disease-free rate and toxicity for men treated with iodine-125 prostate brachytherapy with D90 ≥180 Gy

International Journal of Radiation Oncology Biology Physics

Volumn 78, Issue 2, 2010, Pages 422-427

  Gómez Iturriaga Piña, Alfonso ^a   Crook, Juanita ^a   Borg, Jette ^a   Ma, Clement ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

high dose; iodine 125 brachytherapy; Prostate cancer; toxicity

Indexed keywords

COMPUTERIZED TOMOGRAPHY; DISEASES; DOSIMETRY; INDUSTRIAL CHEMICALS; IODINE; MAGNETIC RESONANCE IMAGING; ONCOLOGY; RADIOTHERAPY; REGRESSION ANALYSIS; RESONANCE; ULTRASONIC IMAGING; ULTRASONOGRAPHY;

ADVERSE EVENTS; AFTER-TREATMENT; BIOCHEMICAL FAILURE; BRACHYTHERAPY; CLINICAL OUTCOME; COMMON TERMINOLOGY CRITERIA; COMPUTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DOSIMETRIC PARAMETER; FLUOROSCOPIC GUIDANCE; GENITOURINARY TOXICITIES; GLEASON SCORES; HIGH DOSE; IODINE-125; LOCAL FAILURE; LOGISTIC REGRESSION ANALYSIS; MONO-THERAPY; NATIONAL CANCER INSTITUTE; PRE-TREATMENT; PROSTATE BRACHYTHERAPY; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; TRANSRECTAL ULTRASONOGRAPHY; UNIVARIATE; UP PERIOD; URINARY RETENTION;

TOXICITY;

IODINE 125; PROSTATE SPECIFIC ANTIGEN; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DOSIMETRY; FLUOROSCOPY; FOLLOW UP; GLEASON SCORE; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RECTUM; RECTUM HEMORRHAGE; TRANSRECTAL ULTRASONOGRAPHY; TREATMENT FAILURE; TREATMENT OUTCOME; URINE RETENTION; BLOOD; GASTROINTESTINAL HEMORRHAGE; MIDDLE AGED; PATHOLOGY; PENIS ERECTION; PROSTATIC NEOPLASMS; RADIATION RESPONSE; URETHRA;

AGED; BRACHYTHERAPY; GASTROINTESTINAL HEMORRHAGE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PENILE ERECTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RECTUM; URETHRA;

EID: 77956535585     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.07.1723     Document Type: Article

References (39)

1. S.T. Peeters, W.D. Heemsbergen, and P.C. Koper Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
2. A.L. Zietman, M.L. DeSilvio, and J.D. Slater Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial JAMA 294 2005 1233 1239
3. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
4. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
5. J.R. Sathya, I.R. Davis, and J.A. Julian Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate J Clin Oncol 23 2005 1192 1199
6. P.A. Kupelian, T.R. Willoughby, and S.L. Meeks Intraprostatic fiducials for localization of the prostate gland: Monitoring intermarker distances during radiation therapy to test for marker stability Int J Radiat Oncol Biol Phys 62 2005 1291 1296
7. M.J. Zelefsky, Z. Fuks, and M. Hunt High-dose intensity modulated radiation therapy for prostate cancer: Early toxicity and biochemical outcome in 772 patients Int J Radiat Oncol Biol Phys 53 2002 1111 1116
8. O. Cahlon, M.J. Zelefsky, and A. Shippy Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes Int J Radiat Oncol Biol Phys 71 2008 330 337
9. L. Potters, Y. Cao, and E. Calugaru A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 50 2001 605 614
10. R.G. Stock, N.N. Stone, and J.A. Cesaretti Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results Int J Radiat Oncol Biol Phys 64 2006 527 533
11. 103Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial Int J Radiat Oncol Biol Phys 57 2003 1297 1303
12. N.N. Stone, L. Potters, and B.J. Davis Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 73 2009 341 346
13. 90 implant doses of 180 Gy or greater Int J Radiat Oncol Biol Phys 70 2008 96 101
14. M. Roach III, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
15. D.A. Kuban, L.B. Levy, and L. Potters Comparison of biochemical failure definitions for permanent prostate brachytherapy Int J Radiat Oncol Biol Phys 65 2006 1487 1493
16. D. Taussky, L. Austen, and A. Toi Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion Int J Radiat Oncol Biol Phys 62 2005 974 980
17. J. Crook, C. Gillan, and I. Yeung PSA kinetics and PSA bounce following permanent seed prostate brachytherapy Int J Radiat Oncol Biol Phys 69 2007 426 433
18. A. Trotti, A.D. Colevas, and A. Setser CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment Semin Radiat Oncol 13 2003 176 181
19. A.M. Amer, J. Mott, and R.I. Mackay Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer Int J Radiat Oncol Biol Phys 56 2003 199 207
20. R. Cheung, S.L. Tucker, and L. Dong Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy Int J Radiat Oncol Biol Phys 56 2003 1234 1240
21. Z. Symon, K.A. Griffith, and P.W. McLaughlin Dose escalation for localized prostate cancer: Substantial benefit observed with 3D conformal therapy Int J Radiat Oncol Biol Phys 57 2003 384 390
22. T.N. Eade, A.L. Hanlon, and E.M. Horwitz What dose of external-beam radiation is high enough for prostate cancer? Int J Radiat Oncol Biol Phys 68 2007 682 689
23. R.G. Stock, N.N. Stone, and A. Tabert A dose-response study for I-125 prostate implants Int J Radiat Oncol Biol Phys 41 1998 101 108
24. 125I prostate implants? A dose-response analysis of biochemical control, posttreatment prostate biopsies, and long-term urinary symptoms Brachytherapy 1 2002 83 89
25. J. Desai, R.G. Stock, and N.N. Stone Acute urinary morbidity following I-125 interstitial implantation of the prostate gland Radiat Oncol Invest 6 1998 135 141
26. Crook J, Patil N, Wallace K, et al. A phase III randomized trial of the timing of meloxicam with iodine 125 prostate brachytherapy. Int J Radiat Oncol Biol Phys. In press.
27. J. Crook, N. Fleshner, and C. Roberts Long-term urinary sequelae following 125 iodine prostate brachytherapy J Urol 179 2008 141 145
28. D.Y. Gelblum, and L. Potters Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer Int J Radiat Oncol Biol Phys 48 2000 119 124
29. A.G. Martin, J. Roy, and L. Beaulieu Permanent prostate implant using high activity seeds and inverse planning with fast simulated annealing algorithm: A 12-year Canadian experience Int J Radiat Oncol Biol Phys 67 2007 334 341
30. 125I prostate brachytherapy Int J Radiat Oncol Biol Phys 55 2003 342 353
31. M.J. Zelefsky, T. Hollister, and A. Raben Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer Int J Radiat Oncol Biol Phys 47 2000 1261 1266
32. M.J. Zelefsky, Y. Yamada, and G.N. Cohen Intraoperative real-time planned conformal prostate brachytherapy: Post-implantation dosimetric outcome and clinical implications Radiother Oncol 84 2007 185 189
33. N. Patil, J. Crook, and E.P. Saibishkumar The effect of obesity on rectal dosimetry after permanent prostate brachytherapy Brachytherapy 8 2009 218 222
34. 125I Int J Radiat Oncol Biol Phys 40 1998 1237 1241
35. 125I transperineal prostate seed implants on commercial treatment planning systems Int J Radiat Oncol Biol Phys 37 1997 737 741
36. N.N. Stone, R.G. Stock, and I. White Patterns of local failure following prostate brachytherapy J Urol 177 2007 1759 1764
37. P.D. Grimm, J.C. Blasko, and J.E. Sylvester 10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy Int J Radiat Oncol Biol Phys 51 2001 31 40
38. A. Pollack, G.K. Zagars, and J.A. Antolak Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: Analysis of a prostate cancer randomized radiation dose escalation trial Int J Radiat Oncol Biol Phys 54 2002 677 685
39. M.J. Zelefsky, Z. Fuks, and M. Hunt High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer J Urol 166 2001 876 881 (Pubitemid 32750970)